GSK Stock Analysis: GlaxoSmithKline | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 99.094m USD | 12M Return: 18.8% | US37733W2044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 254M
EPS Trend: 96.8%
Qual. Beats: 10
Rev. Trend: 96.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GSK plc is a global pharmaceutical company headquartered in London, United Kingdom, that operates across two main segments: Commercial Operations and Total R&D. The company researches, develops, and manufactures a broad portfolio of vaccines, specialty medicines, and general medicines aimed at preventing and treating disease in markets including the UK, the US, and internationally. Its specialty medicines focus on oncology, respiratory/immunology, inflammation, and inhaled therapies for conditions such as HIV, lupus, ovarian cancer, and endometrial cancer. Its vaccine portfolio covers a wide range of diseases including Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, HPV, and Pneumonia, while its general medicines address asthma, COPD, bacterial infections, and inflammatory skin conditions.
The company also pursues discovery and commercialization of oral small molecule therapies in oncology and inflammatory diseases, and maintains multiple R&D collaborations, including partnerships with CureVac on mRNA vaccines, Engitix Ltd on liver fibrosis targets, and AN2 Therapeutics on tuberculosis therapies. Originally founded in 1715, the company was known as GlaxoSmithKline plc until rebranding to GSK plc in May 2022. As a large-cap pharmaceutical issuer listed on the NYSE, GSK operates within a sector characterized by long product development cycles, extensive regulatory oversight, and reliance on patent-protected specialty drugs alongside established vaccine franchises.
- Shingrix vaccine sales growth drives specialty medicines revenue
- Oncology pipeline readouts from CureVac mRNA collaboration advance
- HIV and respiratory drug pricing faces US regulatory pressure
| Net Income: 4.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.63 > 1.0 |
| NWC/Revenue: -11.90% < 20% (prev -11.72%; Δ -0.18% < -1%) |
| CFO/TA 0.14 > 3% & CFO 8.74b > Net Income 4.82b |
| Net Debt (15.9b) to EBITDA (8.80b): 1.80 < 3 |
| Current Ratio: 0.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.03b) vs 12m ago -1.17% < -2% |
| Gross Margin: 72.73% > 18% (prev 71.36%; Δ 1.36% > 0.5%) |
| Asset Turnover: 46.58% > 50% (prev 38.95%; Δ 7.63% > 0%) |
| Interest Coverage Ratio: 9.56 > 6 (EBIT TTM 6.59b / Interest Expense TTM 690.0m) |
| A: -0.06 (Total Current Assets 17.5b - Total Current Liabilities 21.4b) / Total Assets 61.4b |
| B: 0.19 (Retained Earnings 11.4b / Total Assets 61.4b) |
| C: 0.09 (EBIT TTM 6.59b / Avg Total Assets 71.3b) |
| D: 0.40 (Book Value of Equity 17.5b / Total Liabilities 44.3b) |
| Altman-Z'' = 1.22 = BB |
| DSRI: 0.72 (Receivables 8.03b/10.5b, Revenue 33.2b/31.6b) |
| GMI: 0.98 (GM 71.36% / 72.73%) |
| AQI: 1.03 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.05 (Revenue 33.2b / 31.6b) |
| TATA: -0.06 (NI 4.82b - CFO 8.74b) / TA 61.4b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of October 21, 2026, the stock is trading at USD 50.63 with a total of 5,517,667 shares traded. Over the past week, the price has changed by +9.42%, over one month by -0.88%, over three months by +2.09% and over the past year by +18.82%.
Current recommended Stop Loss: 49.20 (which is 2.8% or 1.4 ATR below the current price).
GlaxoSmithKline has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold GSK.
- StrongBuy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 60.5 | 19.5% |
Market Cap GBP = 74.4b (99.1b USD * 0.75098 USD.GBP)
P/E Trailing = 15.6025
P/E Forward = 9.7656
P/S = 2.9845
P/B = 4.3015
P/EG = 6.1023
Revenue TTM = 33.2b GBP
EBIT TTM = 6.59b GBP
EBITDA TTM = 8.80b GBP
Long Term Debt = 14.0b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 4.27b GBP (from shortTermDebt, last quarter)
Debt = 19.0b GBP (from shortLongTermDebtTotal, last quarter) + Leases 830.0m
Net Debt = 15.9b GBP (calculated: Debt 19.0b - CCE 3.09b)
Enterprise Value = 90.3b GBP (74.4b + Debt 19.0b - CCE 3.09b)
Interest Coverage Ratio = 9.56 (Ebit TTM 6.59b / Interest Expense TTM 690.0m)
EV/FCF = 12.94x (Enterprise Value 90.3b / FCF TTM 6.98b)
FCF Yield = 7.73% (FCF TTM 6.98b / Enterprise Value 90.3b)
FCF Margin = 21.02% (FCF TTM 6.98b / Revenue TTM 33.2b)
Net Margin = 14.52% (Net Income TTM 4.82b / Revenue TTM 33.2b)
Gross Margin = 72.73% ((Revenue TTM 33.2b - Cost of Revenue TTM 9.06b) / Revenue TTM)
Gross Margin QoQ = 73.05% (prev 75.42%)
Tobins Q-Ratio = 1.47 (Enterprise Value 90.3b / Total Assets 61.4b)
Interest Expense / Debt = 3.64% (Interest Expense 690.0m / Debt 19.0b)
Taxrate = 10.86% (641.0m / 5.90b)
NOPAT = 5.88b (EBIT 6.59b * (1 - 10.86%))
Current Ratio = 0.82 (Total Current Assets 17.5b / Total Current Liabilities 21.4b)
Debt / Equity = 1.08 (Debt 19.0b / totalStockholderEquity, last quarter 17.5b)
Debt / EBITDA = 1.80 (Net Debt 15.9b / EBITDA 8.80b)
Debt / FCF = 2.27 (Net Debt 15.9b / FCF TTM 6.98b)
Total Stockholder Equity = 19.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.76% (Net Income 4.82b / Total Assets 61.4b)
RoE = 24.35% (Net Income TTM 4.82b / Total Stockholder Equity 19.8b)
RoCE = 19.50% (EBIT 6.59b / Capital Employed (Equity 19.8b + L.T.Debt 14.0b))
RoIC = 13.81% (NOPAT 5.88b / Invested Capital 42.6b)
WACC = 5.46% (E(74.4b)/V(93.4b) * Re(6.02%) + D(19.0b)/V(93.4b) * Rd(3.64%) * (1-Tc(0.11)))
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -61.61 | Cagr: -0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈6.05b ; Y1≈6.94b ; Y5≈10.2b
[DCF] Fair Price = 68.80 (EV 154b - Net Debt 15.9b = Equity 138b / Shares 2.00b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.85 | EPS CAGR: 8.26% | SUE: 2.30 | # QB: 10
Revenue Correlation: 96.73 | Revenue CAGR: 3.58% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.33 | Chg30d=-1.80% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=4.72 | Chg30d=-1.51% | Revisions=-50% | GrowthEPS=+0.2% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=4.92 | Chg30d=-1.14% | Revisions=-50% | GrowthEPS=+4.3% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -73% (up=0, down=8)